Biaxin

FDA: higher mortality seen with Biaxin  Dec 12, 2005
United Press International WASHINGTON, Dec. 12 (UPI) -- There is a possible higher mortality risk with Abbott Lab's Biaxin, the Food and Drug Administration said Monday in an alert. ...

FDA announces alert regarding Biaxin  Dec 14, 2005
myDNA.com, The Food and Drug Administration (FDA) has issued an alert after a study found the antibiotic Biaxin to be associated with an increased mortality rate among ...

Advanced Life Sciences Reports Initiation of Enrollment and First ...  Jan 5, 2006
Yahoo! News (press release) ...double- blind, multicenter, multinational, comparator trial to assess the efficacy and safety of cethromycin in CAP patients versus Biaxin® (clarithromycin). ...

Fitch Affirms Abbott Laboratories 'AA-'; Outlook Stable  Dec 22, 2005
Business Wire (press release), Potential patent exclusivity losses in the intermediate term include an extended-release formulation of Biaxin, Ultane/sevoflurane, and Depakote. ...

Fitch: Abbott Laboratories' Ratings Unchanged After Acquisition ...  Jan 9, 2006
Business Wire (press release), 30, 2005, supported by attractive growth of Humira, offset by generic competition for Synthroid and the immediate-release formulation of Biaxin.